Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 625-633

  Biskup, Saskia ^a,b   West, Andrew B ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Dardarin; Kinase; Leucine rich repeat kinase 2; Molecular genetic; Movement disorder; Neurodegeneration

Indexed keywords

DOPAMINE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; PHOSPHOTRANSFERASE;

AMINO TERMINAL SEQUENCE; APOPTOSIS; CARBOXY TERMINAL SEQUENCE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FAMILIAL DISEASE; GENE ACTIVITY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC COUNSELING; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; POPULATION GENETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SUBSTANTIA NIGRA; SYMPTOM;

EID: 68949125734     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.09.015     Document Type: Review

References (110)

1. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 59 (2006) 591-596
2. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., and Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 (2003) 197-211
3. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51 (2002) 296-301
4. Zimprich A., Muller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M., Lockhart P., Strongosky A., Kachergus J., Calne D.B., Stoessl J., Uitti R.J., Pfeiffer R.F., Trenkwalder C., Homann N., Ott E., Wenzel K., Asmus F., Hardy J., Wszolek Z., and Gasser T. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 74 (2004) 11-19
5. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
6. Bosgraaf L., and Van Haastert P.J. Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 1643 (2003) 5-10
7. Bhandari R., Srinivasan N., Mahaboobi M., Ghanekar Y., Suguna K., and Visweswariah S.S. Functional inactivation of the human guanylyl cyclase C receptor: modeling and mutation of the protein kinase-like domain. Biochemistry 40 (2001) 9196-9206
8. Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G., Sampaio C., Meco G., Barbosa E., Oostra B.A., and Bonifati V. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365 (2005) 412-415
9. Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J., Healy D.G., Holton J.L., Revesz T., and Wood N.W. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 (2005) 415-416
10. Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., Singleton A., and Foroud T. Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 (2005) 410-412
11. Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., and Obata F. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57 (2005) 918-921
12. Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M., Tesei S., Zecchinelli A., Antonini A., Mariani C., Meucci N., Sacilotto G., Sironi F., Salani G., Ferreira J., Chien H.F., Fabrizio E., Vanacore N., Dalla Libera A., Stocchi F., Diroma C., Lamberti P., Sampaio C., Meco G., Barbosa E., Bertoli-Avella A.M., Breedveld G.J., Oostra B.A., Pezzoli G., and Bonifati V. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J. Med. Genet. 42 (2005) e65
13. Gosal D., Ross O.A., Wiley J., Irvine G.B., Johnston J.A., Toft M., Mata I.F., Kachergus J., Hulihan M., Taylor J.P., Lincoln S.J., Farrer M.J., Lynch T., and Mark Gibson J. Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat. Disord. 11 (2005) 349-352
14. Kachergus J., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H., Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K., Farrer M.J., and Toft M. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76 (2005) 672-680
15. Lesage S., Leutenegger A.L., Ibanez P., Janin S., Lohmann E., Durr A., and Brice A. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am. J. Hum. Genet. 77 (2005) 330-332
16. Zabetian C.P., Hutter C.M., Yearout D., Lopez A.N., Factor S.A., Griffith A., Leis B.C., Bird T.D., Nutt J.G., Higgins D.S., Roberts J.W., Kay D.M., Edwards K.L., Samii A., and Payami H. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am. J. Hum. Genet. 79 (2006) 752-758
17. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., Brice A., Aasly J., Zabetian C.P., Goldwurm S., Ferreira J.J., Tolosa E., Kay D.M., Klein C., Williams D.R., Marras C., Lang A.E., Wszolek Z.K., Berciano J., Schapira A.H., Lynch T., Bhatia K.P., Gasser T., Lees A.J., and Wood N.W. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7 (2008) 583-590
18. Kay D.M., Zabetian C.P., Factor S.A., Nutt J.G., Samii A., Griffith A., Bird T.D., Kramer P., Higgins D.S., and Payami H. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov. Disord. 21 (2006) 519-523
19. Bonifati V. LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease. Neurochem. Res. 32 (2007) 1700-1708
20. Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., and Stoessl A.J. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128 (2005) 2777-2785
21. Melrose H.L., Kent C.B., Taylor J.P., Dachsel J.C., Hinkle K.M., Lincoln S.J., Mok S.S., Culvenor J.G., Masters C.L., Tyndall G.M., Bass D.I., Ahmed Z., Andorfer C.A., Ross O.A., Wszolek Z.K., Delldonne A., Dickson D.W., and Farrer M.J. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147 (2007) 1047-1058
22. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
23. Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., and Olson L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59 (2006) 714-719
24. Higashi S., Biskup S., West A.B., Trinkaus D., Dawson V.L., Faull R.L., Waldvogel H.J., Arai H., Dawson T.M., Moore D.J., and Emson P.C. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 1155 (2007) 208-219
25. Higashi S., Moore D.J., Colebrooke R.E., Biskup S., Dawson V.L., Arai H., Dawson T.M., and Emson P.C. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 100 (2007) 368-381
26. Melrose H., Lincoln S., Tyndall G., Dickson D., and Farrer M. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139 (2006) 791-794
27. Simon-Sanchez J., Herranz-Perez V., Olucha-Bordonau F., and Perez-Tur J. LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 23 (2006) 659-666
28. Taymans J.M., Van den Haute C., and Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 98 (2006) 951-961
29. Taylor J.P., Hulihan M.M., Kachergus J.M., Melrose H.L., Lincoln S.J., Hinkle K.M., Stone J.T., Ross O.A., Hauser R., Aasly J., Gasser T., Payami H., Wszolek Z.K., and Farrer M.J. Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 8 (2007) 95-102
30. Westerlund M., Belin A.C., Anvret A., Bickford P., Olson L., and Galter D. Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 152 (2008) 429-436
31. Han B.S., Iacovitti L., Katano T., Hattori N., Seol W., and Kim K.S. Expression of the LRRK2 gene in the midbrain dopaminergic neurons of the substantia nigra. Neurosci. Lett. 3 (2008) 190-194
32. Hatano T., Kubo S., Imai S., Maeda M., Ishikawa K., Mizuno Y., and Hattori N. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 16 (2007) 678-690
33. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., and Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60 (2006) 557-569
34. Perry G., Zhu X., Babar A.K., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., and Chen S.G. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener. Dis. 5 (2008) 222-224
35. Miklossy J., Arai T., Guo J.P., Klegeris A., Yu S., McGeer E.G., and McGeer P.L. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 65 (2006) 953-963
36. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., and Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23 (2006) 329-341
37. Zhu X., Babar A., Siedlak S.L., Yang Q., Ito G., Iwatsubo T., Smith M.A., Perry G., and Chen S.G. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 1 (2006) 17
38. Zhu X., Siedlak S.L., Smith M.A., Perry G., and Chen S.G. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 60 (2006) 617-618 author reply 618-619
39. Biskup S., Moore D.J., Rea A., Lorenz-Deperieux B., Coombes C.E., Dawson V.L., Dawson T.M., and West A.B. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 8 (2007) 102
40. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
41. West A.B., Moore D.J., Choi C., Andrabi S.A., Li X., Dikeman D., Biskup S., Zhang Z., Lim K.L., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16 (2007) 223-232
42. Greggio E., Zambrano I., Kaganovich A., Beilina A., Taymans J.M., Daniels V., Lewis P., Jain S., Ding J., Syed A., Thomas K.J., Baekelandt V., and Cookson M.R. The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J. Biol. Chem. 283 (2008) 16906-16914
43. Hanks S.K., Quinn A.M., and Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241 (1988) 42-52
44. Luzon-Toro B., Rubio de la Torre E., Delgado A., Perez-Tur J., and Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 16 (2007) 2031-2039
45. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
46. Jaleel M., Nichols R.J., Deak M., Campbell D.G., Gillardon F., Knebel A., and Alessi D.R. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405 (2007) 307-317
47. Ito G., Okai T., Fujino G., Takeda K., Ichijo H., Katada T., and Iwatsubo T. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46 (2007) 1380-1388
48. Lewis P.A., Greggio E., Beilina A., Jain S., Baker A., and Cookson M.R. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357 (2007) 668-671
49. Li X., Tan Y.C., Poulose S., Olanow C.W., Huang X.Y., and Yue Z. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103 (2007) 238-247
50. Deng J., Lewis P.A., Greggio E., Sluch E., Beilina A., and Cookson M.R. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1499-1504
51. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., and Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9 (2006) 1231-1233
52. van Egmond W.N., Kortholt A., Plak K., Bosgraaf L., Bosgraaf S., Keizer-Gunnink I., and van Haastert P.J. Intramolecular activation mechanism of the dictyostelium LRRK2-homolog Roco protein GbpC. J. Biol. Chem. 44 (2008) 30412-30420
53. Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., and Ross C.A. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18676-18681
54. Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M.T., and Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16 (2007) 1319-1326
55. Gallo K.A., and Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3 (2002) 663-672
56. Apostol B.L., Simmons D.A., Zuccato C., Illes K., Pallos J., Casale M., Conforti P., Ramos C., Roarke M., Kathuria S., Cattaneo E., Marsh J.L., and Thompson L.M. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 1 (2008) 8-20
57. Besirli C.G., and Johnson Jr. E.M. JNK-independent activation of c-Jun during neuronal apoptosis induced by multiple DNA-damaging agents. J. Biol. Chem. 278 (2003) 22357-22366
58. Lotharius J., Falsig J., van Beek J., Payne S., Dringen R., Brundin P., and Leist M. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25 (2005) 6329-6342
59. Liu Z., Wang X., Yu Y., Li X., Wang T., Jiang H., Ren Q., Jiao Y., Sawa A., Moran T., Ross C.A., Montell C., and Smith W.W. A Drosophila model for LRRK2-linked parkinsonism. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2693-2698
60. Imai Y., Gehrke S., Wang H.Q., Takahashi R., Hasegawa K., Oota E., and Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 18 (2008) 2432-2443
61. Haugarvoll K., Toft M., Ross O.A., White L.R., Aasly J.O., and Farrer M.J. Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. Neurosci. Lett. 416 (2007) 299-301
62. Marin I. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol. Biol. Evol. 23 (2006) 2423-2433
63. Marin I. Ancient origin of the Parkinson disease gene LRRK2. J. Mol. Evol. 67 (2008) 41-50
64. Lee S.B., Kim W., Lee S., and Chung J. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun. 358 (2007) 534-539
65. Wang D., Tang B., Zhao G., Pan Q., Xia K., Bodmer R., and Zhang Z. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener. 3 (2008) 3
66. Sakaguchi-Nakashima A., Meir J.Y., Jin Y., Matsumoto K., and Hisamoto N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 17 (2007) 592-598
67. MacLeod D., Dowman J., Hammond R., Leete T., Inoue K., and Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52 (2006) 587-593
68. Dachsel J.C., Taylor J.P., Mok S.S., Ross O.A., Hinkle K.M., Bailey R.M., Hines J.H., Szutu J., Madden B., Petrucelli L., and Farrer M.J. Identification of potential protein interactors of Lrrk2. Parkinsonism Relat. Disord. 13 (2007) 382-385
69. Gandhi P.N., Wang X., Zhu X., Chen S.G., and Wilson-Delfosse A.L. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86 (2008) 1711-1720
70. Wang L., Xie C., Greggio E., Parisiadou L., Shim H., Sun L., Chandran J., Lin X., Lai C., Yang W.J., Moore D.J., Dawson T.M., Dawson V.L., Chiosis G., Cookson M.R., and Cai H. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28 (2008) 3384-3391
71. Burckstummer T., Bennett K.L., Preradovic A., Schutze G., Hantschel O., Superti-Furga G., and Bauch A. An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat. Methods 3 (2006) 1013-1019
72. Duda J.E., Giasson B.I., Mabon M.E., Miller D.C., Golbe L.I., Lee V.M., and Trojanowski J.Q. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 104 (2002) 7-11
73. Golbe L.I., Di Iorio G., Sanges G., Lazzarini A.M., La Sala S., Bonavita V., and Duvoisin R.C. Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann. Neurol. 40 (1996) 767-775
74. Nichols W.C., Elsaesser V.E., Pankratz N., Pauciulo M.W., Marek D.K., Halter C.A., Rudolph A., Shults C.W., and Foroud T. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69 (2007) 1737-1744
75. Xiromerisiou G., Hadjigeorgiou G.M., Gourbali V., Johnson J., Papakonstantinou I., Papadimitriou A., and Singleton A.B. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur. J. Neurol. 14 (2007) 7-11
76. Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., and Singleton A.B. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum. Mutat. 29 (2008) 485-490
77. Berg D., Schweitzer K., Leitner P., Zimprich A., Lichtner P., Belcredi P., Brussel T., Schulte C., Maass S., and Nagele T. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 128 (2005) 3000-3011
78. Haubenberger D., Bonelli S., Hotzy C., Leitner P., Lichtner P., Samal D., Katzenschlager R., Djamshidian A., Brucke T., Steffelbauer M., Bancher C., Grossmann J., Ransmayr G., Strom T.M., Meitinger T., Gasser T., Auff E., and Zimprich A. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov. Disord. 22 (2007) 1640-1643
79. Skipper L., Shen H., Chua E., Bonnard C., Kolatkar P., Tan L.C., Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C., Yuen Y., Farrer M., Liu J.J., and Tan E.K. Analysis of LRRK2 functional domains in nondominant Parkinson disease. Neurology 65 (2005) 1319-1321
80. Schlitter A.M., Woitalla D., Mueller T., Epplen J.T., and Dekomien G. The LRRK2 gene in Parkinson's disease: mutation screening in patients from Germany. J. Neurol. Neurosurg. Psychiatry 77 (2006) 891-892
81. Chen-Plotkin A.S., Yuan W., Anderson C., McCarty Wood E., Hurtig H.I., Clark C.M., Miller B.L., Lee V.M., Trojanowski J.Q., Grossman M., and Van Deerlin V.M. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations. Neurology 70 (2008) 521-527
82. Nuytemans K., Rademakers R., Theuns J., Pals P., Engelborghs S., Pickut B., de Pooter T., Peeters K., Mattheijssens M., Van den Broeck M., Cras P., De Deyn P.P., and van Broeckhoven C. Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients. Eur. J. Hum. Genet. 16 (2008) 471-479
83. Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S., Fisman G.K., Al-Khairallah T., St George-Hyslop P., Singleton A., and Rogaeva E. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65 (2005) 696-700
84. Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C., Yearout D., Raskind W.H., and Griffith A. A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 (2005) 741-744
85. Mata I.F., Kachergus J.M., Taylor J.P., Lincoln S., Aasly J., Lynch T., Hulihan M.M., Cobb S.A., Wu R.M., Lu C.S., Lahoz C., Wszolek Z.K., and Farrer M.J. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6 (2005) 171-177
86. Pchelina S.N., Yakimovskii A.F., Emelyanov A.K., Ivanova O.N., Schwarzman A.L., and Singleton A.B. Screening for LRRK2 mutations in patients with Parkinson's disease in Russia: identification of a novel LRRK2 variant. Eur. J. Neurol. 15 (2008) 692-696
87. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., and Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128 (2005) 2786-2796
88. Lesage S., Janin S., Lohmann E., Leutenegger A.L., Leclere L., Viallet F., Pollak P., Durif F., Thobois S., Layet V., Vidailhet M., Agid Y., Durr A., Brice A., Bonnet A.M., Borg M., Broussolle E., Damier P., Destee A., Martinez M., Penet C., Rasco O., Tison F., Tranchan C., and Verin M. LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans. Arch. Neurol. 64 (2007) 425-430
89. Clarimon J., Pagonabarraga J., Paisan-Ruiz C., Campolongo A., Pascual-Sedano B., Marti-Masso J.F., Singleton A.B., and Kulisevsky J. Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Mov. Disord. 23 (2008) 518-523
90. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., Lipton R.B., Soto-Valencia J., Risch N., and Bressman S.B. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
91. Moller J.C., Rissling I., Mylius V., Hoft C., Eggert K.M., and Oertel W.H. The prevalence of the G2019S and R1441C/G/H mutations in LRRK2 in German patients with Parkinson's disease. Eur. J. Neurol. 15 (2008) 743-745
92. Bras J.M., Guerreiro R.J., Ribeiro M.H., Januario C., Morgadinho A., Oliveira C.R., Cunha L., Hardy J., and Singleton A. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov. Disord. 20 (2005) 1653-1655
93. Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J., Rohe C.F., Riboldazzi G., Antonini A., Albani G., Mauro A., Marconi R., Abbruzzese G., Lopiano L., Fincati E., Guidi M., Marini P., Stocchi F., Onofrj M., Toni V., Tinazzi M., Fabbrini G., Lamberti P., Vanacore N., Meco G., Leitner P., Uitti R.J., Wszolek Z.K., Gasser T., Simons E.J., Breedveld G.J., Goldwurm S., Pezzoli G., Sampaio C., Barbosa E., Martignoni E., Oostra B.A., and Bonifati V. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur. J. Hum. Genet. 14 (2006) 322-331
94. Mata I.F., Ross O.A., Kachergus J., Huerta C., Ribacoba R., Moris G., Blazquez M., Guisasola L.M., Salvador C., Martinez C., Farrer M., and Alvarez V. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur. J. Neurol. 13 (2006) 391-394
95. Lesage S., Leclere L., Lohmann E., Borg M., Ruberg M., Durr A., and Brice A. Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease. Neurodegener. Dis. 4 (2007) 195-198
96. Mellick G.D., Siebert G.A., Funayama M., Buchanan D.D., Li Y., Imamichi Y., Yoshino H., Silburn P.A., and Hattori N. Screening PARK genes for mutations in early-onset Parkinson's disease patients from Queensland, Australia. Parkinsonism Relat. Disord. XX (2008) 1-5
97. Pimentel M.M., Moura K.C., Abdalla C.B., Pereira J.S., de Rosso A.L., Nicaretta D.H., Campos Jr. M., de Almeida R.M., dos Santos J.M., Bastos I.C., Mendes M.F., Maultasch H., Costa F.H., Werneck A.L., and Santos-Reboucas C.B. A study of LRRK2 mutations and Parkinson's disease in Brazil. Neurosci. Lett. 433 (2008) 17-21
98. Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J., Hulihan M., White L.R., and Farrer M. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann. Neurol. 57 (2005) 762-765
99. Grimes D.A., Racacho L., Han F., Panisset M., and Bulman D.E. LRRK2 screening in a Canadian Parkinson's disease cohort. Can. J. Neurol. Sci. 34 (2007) 336-338
100. Dupre N., Riviere J.B., Myers R.H., Provencher P., Pourcher E., Emond F., and Rouleau G.A. LRRK2 is not a significant cause of Parkinson's disease in French-Canadians. Can. J. Neurol. Sci. 34 (2007) 333-335
101. Kalinderi K., Fidani L., Bostantjopoulou S., Katsarou Z., and Kotsis A. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. Eur. J. Neurol. 14 (2007) 1088-1090
102. Bialecka M., Hui S., Klodowska-Duda G., Opala G., Tan E.K., and Drozdzik M. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. Neurosci. Lett. 390 (2005) 1-3
103. Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L., Fook-Chong S., Tang S., Chua E., Yuen Y., Tan L., Pavanni R., Wong M.C., Kolatkar P., Lu C.S., Bonifati V., and Liu J.J. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum. Genet. 120 (2007) 857-863
104. Ross O.A., Wu Y.R., Lee M.C., Funayama M., Chen M.L., Soto A.I., Mata I.F., Lee-Chen G.J., Chen C.M., Tang M., Zhao Y., Hattori N., Farrer M.J., Tan E.K., and Wu R.M. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64 (2008) 88-92
105. Gaig C., Ezquerra M., Marti M.J., Valldeoriola F., Munoz E., Llado A., Rey M.J., Cardozo A., Molinuevo J.L., and Tolosa E. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J. Neurol. Sci. 270 (2008) 94-98
106. Ross O.A., Toft M., Whittle A.J., Johnson J.L., Papapetropoulos S., Mash D.C., Litvan I., Gordon M.F., Wszolek Z.K., Farrer M.J., and Dickson D.W. Lrrk2 and Lewy body disease. Ann. Neurol. 59 (2006) 388-393
107. Giasson B.I., Covy J.P., Bonini N.M., Hurtig H.I., Farrer M.J., Trojanowski J.Q., and Van Deerlin V.M. Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59 (2006) 315-322
108. Rajput A., Dickson D.W., Robinson C.A., Ross O.A., Dachsel J.C., Lincoln S.J., Cobb S.A., Rajput M.L., and Farrer M.J. Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology 67 (2006) 1506-1508
109. Wszolek Z.K., Pfeiffer R.F., Tsuboi Y., Uitti R.J., McComb R.D., Stoessl A.J., Strongosky A.J., Zimprich A., Muller-Myhsok B., Farrer M.J., Gasser T., Calne D.B., and Dickson D.W. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62 (2004) 1619-1622
110. Giordana M.T., D'Agostino C., Albani G., Mauro A., Di Fonzo A., Antonini A., and Bonifati V. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation. Mov. Disord. 22 (2007) 275-278